Literature DB >> 11710931

Broad-spectrum sunscreens provide better protection from the suppression of the elicitation phase of delayed-type hypersensitivity response in humans.

D D Moyal1, A M Fourtanier.   

Abstract

It is well established that ultraviolet radiation has immunomodulatory effects that may be involved in skin cancer. Recent studies have shown that ultraviolet A radiation (320-400 nm) as well as ultraviolet B (290-320 nm) is immunosuppressive. This means sunscreens that mainly absorb ultraviolet B (protection against erythema) may be less effective in preventing ultraviolet radiation-induced immunosuppression than broad-spectrum products. We have studied the effects of ultraviolet A exposure on the human delayed-type hypersensitivity response and compared the efficacy of sunscreens having different levels of ultraviolet A protection under both solar-simulated radiation and outdoor real-life solar exposure conditions. Delayed-type hypersensitivity was assessed using recall antigens. In a first study, two groups of volunteers were exposed to ultraviolet A (either full spectrum ultraviolet A or ultraviolet A1) without prior application of sunscreen and they were shown to exhibit significantly reduced delayed-type hypersensitivity responses. In order to compare the efficacy of sunscreens in preventing photoimmunosuppression, three groups of subjects received 10 cumulative exposures to solar-simulated radiation; one group was exposed unprotected and the other two were exposed after being applied either a ultraviolet B or a broad-spectrum sunscreen, each with the same sun protection factor 9, but with different ultraviolet A protection factors 9 and 2. Then, an outdoor study was conducted in which delayed-type hypersensitivity was assessed before and after six daily exposures. Two different groups of subjects were treated with one of two sunscreens having the same sun protection factor 25 but different ultraviolet A-protection factors. In unprotected volunteers, responses to delayed-type hypersensitivity tests were significantly reduced irrespective of ultraviolet exposure conditions (full spectrum ultraviolet A, ultraviolet A1, solar-simulated radiation). The ultraviolet B sunscreen failed to protect from solar- simulated radiation-induced immunosuppression. In contrast, the broad-spectrum sunscreen having the same sun protection factor but providing high protection in the ultraviolet A range significantly reduced local ultraviolet-induced immunosuppression and prevented the distal effects. In the outdoor study, as compared with delayed-type hypersensitivity responses obtained before sun exposure, no alteration of immune response was detected when the skin was protected by broad-spectrum sunscreen sun protection factor 25 and ultraviolet A-protection factor 14. Conversely, a broad-spectrum sunscreen sun protection factor 25 ultraviolet A-protection factor 6 failed to protect against the sun-impaired response. The above studies clearly demonstrate the role of ultraviolet A in the induction of photoimmunosuppression together with the need for sunscreen products providing efficient photoprotection throughout the entire ultraviolet spectrum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710931     DOI: 10.1046/j.0022-202x.2001.01545.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Are there differences in immune responses following delivery of vaccines through acutely or chronically sun-exposed compared with sun-unexposed skin?

Authors:  Prue H Hart; Mary Norval
Journal:  Immunology       Date:  2019-11-06       Impact factor: 7.397

Review 2.  UVB-Induced Microvesicle Particle Release and Its Effects on the Cutaneous Microenvironment.

Authors:  Timothy C Frommeyer; Michael M Gilbert; Garrett V Brittain; Tongfan Wu; Trang Q Nguyen; Craig A Rohan; Jeffrey B Travers
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

3.  Suppression of an established immune response by UVA--a critical role for mast cells.

Authors:  Stephen E Ullrich; Dat X Nghiem; Polina Khaskina
Journal:  Photochem Photobiol       Date:  2007 Sep-Oct       Impact factor: 3.421

Review 4.  Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.

Authors:  Elisabetta Damiani; Stephen E Ullrich
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

5.  Diversity of biological effects induced by longwave UVA rays (UVA1) in reconstructed skin.

Authors:  Claire Marionnet; Cécile Pierrard; Christelle Golebiewski; Françoise Bernerd
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

Review 6.  Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function.

Authors:  Daniela Martini; Donato Angelino; Chiara Cortelazzi; Ivana Zavaroni; Giorgio Bedogni; Marilena Musci; Carlo Pruneti; Giovanni Passeri; Marco Ventura; Daniela Galli; Prisco Mirandola; Marco Vitale; Alessandra Dei Cas; Riccardo C Bonadonna; Sergio Di Nuzzo; Maria Beatrice De Felici; Daniele Del Rio
Journal:  Nutrients       Date:  2017-12-22       Impact factor: 5.717

Review 7.  More Than Skin Deep: Autophagy Is Vital for Skin Barrier Function.

Authors:  Payel Sil; Sing-Wai Wong; Jennifer Martinez
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

Review 8.  The Damaging Effects of Long UVA (UVA1) Rays: A Major Challenge to Preserve Skin Health and Integrity.

Authors:  Françoise Bernerd; Thierry Passeron; Isabelle Castiel; Claire Marionnet
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

9.  Skin Hyperpigmentation in Indian Population: Insights and Best Practice.

Authors:  Stephanie Nouveau; Divya Agrawal; Malavika Kohli; Francoise Bernerd; Namita Misra; Chitra Shivanand Nayak
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.